Organophosphate Poisoning: A Comprehensive Reference for MD Emergency Medicine

1. MECHANISM OF TOXICITY

• Muscarinic receptors (postganglionic parasympathetic): glands, smooth muscle, heart
• Nicotinic receptors (autonomic ganglia, neuromuscular junction): skeletal muscle
• CNS receptors: NMDA-R, muscarinic, plus direct CNS ACh accumulation

2. CLINICAL FEATURES

Muscarinic (SLUDGE / DUMBELS)

Nicotinic (autonomic ganglia + NMJ)

• Muscle fasciculations, weakness, paralysis
• Tachycardia, hypertension (early - NMJ nicotinic)
• Diaphoresis (sympathetic cholinergic)

CNS

• Anxiety, restlessness, seizures, coma
• NMDA-R involvement + ACh accumulation drives seizures

Note: Mydriasis can occur despite being classically expected to be miotic if nicotinic/sympathetic effects predominate - a key clinical trap.

3. ED MANAGEMENT

Step 1: Personal Protection First

• Healthcare workers must wear nitrile or neoprene gloves (latex is inadequate against OPs), gown, eye protection.
• Remove patient's clothing; wash skin and hair with copious soap and water.
• Secondary contamination of staff is a real and documented hazard.

Step 2: ABCDE Stabilization

• Airway: Early intubation for respiratory failure. Use succinylcholine with caution - pseudocholinesterase inhibition by OPs prolongs neuromuscular blockade dramatically. Prefer rocuronium (non-depolarizing).
• Breathing: Respiratory failure from bronchospasm + bronchorrhea + diaphragmatic paralysis is the primary cause of death.
• Circulation: Establish IV/IO access (IO is equivalent to IV when providers are in PPE gear per Medscape/AHA 2023 data).

Step 3: Decontamination

• Activated charcoal: 1 g/kg if the patient presents within 1-2 hours of ingestion, with intact airway. Gastric lavage is now discouraged - meta-analyses show doubtful or harmful efficacy (Chauhan et al., WJ Emerg Med, 2026, PMID: 42258859).

Step 4: Antidote Therapy

A. ATROPINE - Cornerstone

• Goal: Dry secretions (bronchorrhea), not pupil dilation or heart rate.
• Endpoint: Cessation of bronchorrhea and bronchospasm. Pupils, HR, and skin are unreliable endpoints.
• Dosing (Adults):
  • Mild: 1-2 mg IV q5-10 min
  • Moderate-severe: Start 2-4 mg IV, double the dose every 5-10 min until secretions dry
  • Massive doses may be required: 10s to 100s of mg over 24 hours
  • AHA 2023 guidelines recommend immediate atropine for bronchospasm, bronchorrhea, seizures, or significant bradycardia
• Atropine does NOT reverse nicotinic effects (paralysis, fasciculations, tachycardia)

B. PRALIDOXIME (2-PAM) - Oxime

• Reactivates AChE if given before aging occurs
• Dosing: 1-2 g IV slow infusion over 15-30 min; then 200-400 mg/hr continuous infusion
• Controversy (crucial for exams):
  • A 2020 meta-analysis found no benefit over atropine alone, and possibly increased incidence of intermediate syndrome with pralidoxime
  • The 2026 umbrella review (Chauhan et al., PMID 42258859) confirms: "oximes showed neither benefit nor harm"
  • AHA 2023 states oximes "are not universally effective"
  • Current pragmatic stance: Give pralidoxime early in severe poisoning (fasciculations, weakness, paralysis) and when carbamate vs OP cannot be distinguished. Do not delay atropine for it.

C. BENZODIAZEPINES

• Diazepam or midazolam for seizures and agitation
• Seizures in OP poisoning are GABA-ergic + NMDA-R mediated; standard AED protocols apply
• Early benzodiazepines reduce neurological damage (animal data suggests combination with atropine/pralidoxime)

D. Glycopyrrolate (Emerging)

• Quaternary ammonium - does not cross BBB, thus avoids CNS atropinization effects
• Systematic review (Rashid et al., PMID 38797902, 2025): fewer hospitalization days, comparable outcomes; evidence still insufficient for routine recommendation.

Step 5: Adjunct Measures

• Magnesium sulfate: Reduces ACh release at synapses; narrative reviews suggest benefit but 2026 umbrella review recommends against routine use
• IV Lipid Emulsion (ILE): Theoretical sequestration of lipid-soluble OPs; evidence is weak, not currently recommended routinely
• Alkalinization: Not effective per current evidence
• Fresh Frozen Plasma: Contains butyrylcholinesterase as a bioscavenger; adjunctive use studied but not standard

4. COMPLICATIONS

5. THREE CLINICAL SYNDROMES IN OP POISONING

I. Acute Cholinergic Crisis (Phase 1)

• Onset: minutes to hours after exposure
• SLUDGE + DUMBELS + Killer Bs + CNS effects
• Responds to atropine + pralidoxime

II. Intermediate Syndrome (IMS) - Phase 2

• Onset: 24-96 hours after the acute cholinergic phase has resolved
• Described first by Senanayake and Karalliedde
• Features:
  • Weakness/paralysis of proximal limb muscles
  • Weakness of neck flexors
  • Cranial nerve palsies (cranial nerve VI, VII, X - ophthalmoplegia, facial weakness, dysphagia)
  • Respiratory muscle paralysis - the main cause of death in IMS
• Pathophysiology: Postsynaptic NMJ dysfunction; not reversed by atropine or pralidoxime
• Treatment: Supportive only; ventilatory support until recovery (2-3 weeks)
• Compounds most associated: fat-soluble OPs (fenthion, dimethoate)

III. OP-Induced Delayed Neuropathy (OPIDN) - Phase 3

• Onset: 2-5 weeks after acute poisoning
• Distal symmetrical sensorimotor polyneuropathy (predominantly motor)
• Begins with numbness/burning in feet, ascends
• Caused by inhibition of neuropathy target esterase (NTE); "dying-back" axonopathy of longest fibers
• Later: signs of corticospinal tract damage (spasticity, pyramidal signs) - especially with TOCP
• No effective treatment; recovery is variable and often incomplete
• Compounds: triorthocresyl phosphate (TOCP), mipafox, leptophos
• - Adams & Victor's Principles of Neurology, 12th Ed.

6. DIFFICULTIES IN ED MANAGEMENT AND SOLUTIONS

7. LONG-TERM SEQUELAE

Neurological

• OPIDN: distal motor > sensory polyneuropathy, spasticity (irreversible in severe cases)
• Chronic neuropsychiatric syndrome: memory impairment, cognitive dysfunction, depression, anxiety, PTSD
• Parkinson's-like syndrome: evidence from chronic occupational exposure studies
• Persistent EEG changes: epileptiform activity documented years after exposure
• Behavioral consequences: affective disorders, sensorimotor deficits (2026 review, Bel et al., PMID 41740636)

Endocrine

• New-onset diabetes mellitus: OP compounds disrupt insulin secretion via pancreatic beta-cell cholinergic dysregulation and oxidative stress (Chung et al., PMID 34888010)

Cardiovascular

• Chronic arrhythmias, QTc prolongation risk

Pulmonary

• Chronic restrictive lung disease from recurrent aspiration and parenchymal damage

Developmental (prenatal exposure)

• Impaired neurodevelopment at 2 years: prenatal OP exposure associated with reduced cognitive scores (Wang et al., 2023, Environmental Health Perspectives)

8. RECENT ADVANCES IN OP MANAGEMENT (2023-2026)

A. Bioscavengers

• Recombinant human butyrylcholinesterase (rHuBChE): pre-exposure prophylaxis and post-exposure treatment; sequesters OPs before they reach AChE
• Paraoxonase-1 (PON1): hydrolyzes OPs; polymorphisms influence susceptibility; recombinant PON1 under investigation
• Novel engineered albumin-based scavengers

B. Next-Generation Oxime Reactivators

• K-oximes (K027, K203): broader spectrum reactivation, more effective against aged complexes and nerve agents
• Combination oxime strategies

C. Neuroprotective Agents

• Ketamine (NMDA antagonist): added to standard treatment in sarin-poisoned animal models; clinically relevant additional neuroprotection even with delayed administration
• Antioxidants (N-acetylcysteine, Vitamin C): reduce oxidative stress-mediated neuronal damage post-exposure

D. Hemoadsorption / Extracorporeal Techniques

• Hemoadsorption (e.g., CytoSorb cartridge): removes lipophilic toxins; emerging case reports of use in neurotoxic poisoning (Hernandez-Vaquero et al., PMID 41211333, 2025)
• Plasma exchange + hemoperfusion: reported benefit in Chinese studies; umbrella review cautions very low evidence quality

E. Point-of-Care Diagnostics

• Portable biosensors for rapid OP detection in field/mass casualty settings: electrochemical, optical, and immunochromatographic platforms under development

F. Magnesium Sulfate

• Acts by blocking presynaptic ACh release; scoping review (2025) suggests reduced ICU stays (Nelakuditi et al., PMID 39188488); umbrella review 2026 still recommends against routine use

G. Glycopyrrolate as Atropine Alternative

• Systematic review 2025: comparable efficacy to atropine, fewer CNS adverse effects (tachycardia, delirium), potentially fewer hospitalization days

H. Penehyclidine (China)

• Anticholinergic with combined muscarinic + nicotinic blockade; widely used in China; 2026 umbrella review: insufficient evidence for routine use outside China

I. AHA 2023 Poisoning Guidelines

• First major AHA guidance specifically addressing life-threatening poisonings including OPs
• Immediate atropine for bronchospasm/bronchorrhea/seizures/bradycardia
• Oximes: consider in significant poisoning with fasciculations/weakness; acknowledge lack of universal effectiveness

9. TRICKY EXAM QUESTIONS FOR MD EMERGENCY MEDICINE VIVA

1. For QTc: Magnesium stabilizes the cardiac membrane and reduces Torsades de Pointes risk - standard EM practice.
2. For OP antidote effect: MgSO4 acts as a presynaptic calcium channel blocker, reducing voltage-gated Ca2+ influx and thus decreasing ACh vesicle release at cholinergic synapses. This theoretically reduces ACh accumulation independent of AChE inhibition.

1. Carbamate-AChE binding is reversible and spontaneously hydrolyzes within 24-48 hours (carbamates do NOT age).
2. Pralidoxime in carbamate poisoning may actually worsen toxicity by forming a carbamyl-pralidoxime complex that is itself toxic.
3. Treatment: Atropine only (same endpoint - dry secretions); supportive care; the patient will recover as the carbamate dissociates spontaneously.

• Distal symmetrical sensorimotor polyneuropathy (motor > sensory)
• Compounds: TOCP, mipafox, leptophos
• Later phase: corticospinal tract signs (spasticity, hyperreflexia) - the combined picture is called central-peripheral distal axonopathy

• A pivotal RCT (Eddleston et al., Lancet) found high-dose pralidoxime (2 g IV then 1 g/h) was associated with INCREASED mortality versus placebo
• It may delay effective treatment (atropine is downstaged) and paradoxically worsen IMS
• Low-dose continuous infusion (1 g/4 h) showed some benefit in moderately severe cases in early treatment

• Atropine remains the only clearly effective treatment
• Oximes: neither benefit nor harm overall
• Gastric lavage: doubtful or harmful
• Penehyclidine, xuebijing, rhubarb, lipid emulsions, magnesium, hemoperfusion/plasma exchange: all reported mortality reduction in low-quality (mostly Chinese) studies but evidence insufficient for routine recommendation
• Alkalinization: ineffective

1. Staff PPE and scene safety first - Sarin off-gasses; secondary contamination of healthcare workers can incapacitate the response. Without PPE, you lose responders. Nitrile/butyl rubber suits + SCBA in hot zone; minimum: nitrile gloves + face shield in ED decontamination zone.
2. Decontamination before entry to ED - Strip and wash all patients before they enter the main ED; even 0.5 mL of liquid VX on skin is lethal; gaseous sarin evaporates from clothing and re-exposes providers indoors.
3. Triage and immediate atropinization - Use the Mark 1/DuoDote auto-injectors (atropine 2.1 mg + pralidoxime 600 mg IM) for ambulatory/mild casualties; IV/IO access for severe (unconscious/seizing) patients. Priority: respiratory symptoms (bronchorrhea > bronchospasm) and seizures. Unconscious seizing patients get atropine + benzodiazepine first. IO access is equivalent to IV and achievable in PPE (Medscape/AHA 2023). Triage to respiratory status, not level of consciousness alone, since miosis alone is not lethal.

Sources

• Rosen's Emergency Medicine: Concepts and Clinical Practice, 10th Ed., Chapter 152
• Adams & Victor's Principles of Neurology, 12th Ed., Chapter: Phosphorus and Organophosphate Poisoning
• Chauhan V et al. (2026). Therapeutic Interventions in Organophosphate Poisoning: An Umbrella Review. West J Emerg Med. PMID: 42258859
• Zoofaghari S et al. (2024). Organophosphate Poisoning: Review of Prognosis and Management. Adv Biomed Res. PMID: 39512408
• Galindo Alonso L et al. (2025). Advances in the Detection and Management of Organophosphate Poisoning. Am J Ther. PMID: 41099740
• Rashid M et al. (2025). Efficacy and Safety of Glycopyrrolate in OPC Poisoning: Systematic Review. Curr Rev Clin Exp Pharmacol. PMID: 38797902
• Bel R et al. (2026). Behavioral consequences of organophosphorus poisoning. Neurosci Biobehav Rev. PMID: 41740636
• AHA 2023 Guidelines for Management of Life-Threatening Poisonings
• Medscape: Organophosphate Toxicity Treatment & Management (updated 2026)